These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Completed, but no date||2009-016449-24||Regeneración del cartílago articular en gonartrosis de IIº y IIIer grados mediante infiltración articular de Xcel-m-condro-alfa*||bad-data|
|Exempt||2011-006270-13||A phase I-IIa safety and efficacy pilot clinical trial of intraarticular administration of autologous mesenchymal stem cells in meniscus injury||2017-03-04||not-yet-due|
|Exempt||2012-000734-19||Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis||2019-09-25||not-yet-due|
|Not reported||2013-005025-23||A phase IIa, unicenter, prospective, randomized, parallel, two-arms, single-dose, open-label with blinded assessor pilot clinical trial to assess ex vivo expanded adult autologous mesenchymal stromal ...||2019-03-05||due-trials|
|Exempt Terminated||2015-000510-22||CLINICAL EFFICACY OF PLATELET GEL FROM CORD BLOOD FOR THE TREATMENT OF DIABETIC FOOT ULCERS||not-yet-due|
|Exempt||2015-005786-23||A phase I/IIa, randomized, double-blind, single-dose, placebo controlled, two-way crossover clinical trial to assess the safety and to obtain efficacy data in intrathecal administration of expanded Wh...||not-yet-due|
|Exempt Terminated||2016-001841-23||A multicenter, randomized, open-label, two-arms phase I/II clinical trial to asses efficacy and safety of cord blood eye drops in neurotrophic keratopathy||2020-03-12||not-yet-due|
|Exempt||2018-000911-25||A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoieti...||not-yet-due|
|Ongoing||2018-001867-22||TRANSFUSION OF RED BLOOD CELLS, TRANEXAMIC ACID AND FIBRINOGEN CONCENTRATE FOR SEVERE TRAUMA HEMORRHAGE AT PRE-HOSPITAL PHASE OF CARE. A PILOT TRIAL.||not-yet-due|
|Exempt||2020-001505-22||Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in ...||not-yet-due|